Tech Guru
Long/short equity, biotech, healthcare, tech

Rockwell Medical CRUISE Data Is Positive - Implications For The Next Move

On Thursday morning, Rockwell Medical (NASDAQ:RMTI) announced positive top-line results from CRUISE-1, the first of two Phase 3 trials for SFP, which is simply a salt form of iron that can be added to dialysate to maintain chronic kidney disease (CKD) patients' hemoglobin. Iron deficiency anemia is an ongoing concern for dialysis patients, and SFP has the potential to become the market leader in iron replacement. Not long ago, I wrote an article arguing that due to pending catalysts and the advancement of their business model, the short thesis for Rockwell Medical had played out. The successful release of CRUISE-1 data confirms one of the planks of my argument, and these positive results bode well for CRUISE...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details